None | Atorvastatin | Simvastatin | Rosuvastatin | Pravastatin | |
---|---|---|---|---|---|
(N = 2043) | (N = 4415) | (N = 4462) | (N = 713) | (N = 1092) | |
Composite outcomea | |||||
No of events/person-years | 217/7032 | 398/16,840 | 342/18,287 | 41/2894 | 97/4461 |
Absolute ratesb (95% CI) | 30.9 (27.0–35.3) | 23.6 (21.4–26.1) | 18.7 (16.8–20.8) | 14.2 (10.4–19.2) | 21.7 (17.8–26.5) |
HRc (95% CI) | 1 (reference) | 0.75 (0.64–0.89) | 0.59 (0.50–0.70) | 0.45 (0.32–0.62) | 0.68 (0.54–0.87) |
aHRd (95% CI) | 1 (reference) | 0.82 (0.68–0.98) | 0.67 (0.55–0.82) | 0.56 (0.39–0.81) | 0.78 (0.60–1.01) |
All-cause mortality | |||||
No of events/person-years | 177/7098 | 203/17,229 | 162/18,710 | 17/2947 | 33/4616 |
Absolute rates (95% CI) | 24.9 (21.5–28.9) | 11.8 (10.3–13.5) | 8.7 (7.4–10.1) | 5.8 (3.6–9.3) | 7.1 (5.1–10.1) |
HR (95% CI) | 1 (reference) | 0.45 (0.37–0.55) | 0.32 (0.26–0.40) | 0.22 (0.13–0.36) | 0.27 (0.19–0.39) |
aHR (95% CI) | 1 (reference) | 0.61 (0.48–0.78) | 0.49 (0.38–0.64) | 0.39 (0.22–0.67) | 0.39 (0.26–0.60) |
Acute myocardial infarction (AMI) | |||||
No of events/person-years | 5/7094 | 26/17,168 | 21/18,670 | 2/2948 | 11/4590 |
Absolute rates (95% CI) | 0.7 (0.3–1.7) | 1.5 (1.0–2.2) | 1.1 (0.7–1.7) | 0.7 (0.2–2.7) | 2.4 (1.3–4.3) |
HR (95% CI) | 1 (reference) | 2.17 (0.83–5.65) | 1.62 (0.61–4.30) | 0.98 (0.19–5.03) | 3.45 (1.20–9.94) |
aHR (95% CI) | 1 (reference) | 1.42 (0.53–3.78) | 0.88 (0.32–2.40) | 0.63 (0.12–3.33) | 1.61 (0.54–3.78) |
Non-fatal stroke | |||||
No of events/person-years | 34/7051 | 168/16,919 | 158/18,337 | 22/2896 | 53/4489 |
Absolute rates (95% CI) | 4.8 (3.4–6.7) | 9.9 (8.5–11.6) | 8.6 (7.4–10.1) | 7.6 (5.0–11.5) | 11.8 (9.0–15.5) |
HR (95% CI) | 1 (reference) | 2.07 (1.43–2.99) | 1.80 (1.24–2.61) | 1.59 (0.93–2.72) | 2.47 (1.61–3.80) |
aHR (95% CI) | 1 (reference) | 1.82 (1.22–2.72) | 1.67 (1.11–2.51) | 1.64 (0.91–2.94) | 2.42 (1.52–3.84) |